See a real life example of how PTMScan technology can facilitate translational discovery. In this short video we describe how CST not only identified a major driver of NSCLC, which can respond to an FDA approved drug, but went a step further and developed an antibody that can be used to test which patients might be candidates for treatment. All thanks to the power of simplified proteomics.
The Potential of Proteomics: A Clear Path to Discovery - Part II
Missed Part I? Watch it here.